PL 4902
Alternative Names: PL-4902Latest Information Update: 29 Sep 2023
At a glance
- Originator Jiangsu ProteLight Pharmaceutical and Biotechnology
- Class Antibacterials; Peptides
- Mechanism of Action Cell membrane structure modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lung disorders
Most Recent Events
- 07 Sep 2023 Preclinical trials in Lung disorders in China (Injection), before September 2023 (Jiangsu Protelight Pharmaceutical & Biotechnology pipeline, September 2023)